Top Markets
#1 Velas Velas +480.91%
#2 Siren Siren +109.58%
#3 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#4 Venom Venom +45.46%
#5 Gigachad Gigachad +23.69%
#6 Ontology Ontology +20.18%
#7 Scor Scor +17.06%
#8 Dacxi Dacxi +16.49%
#9 Strategic Oil Supply Strategic Oil Supply +15.04%
#10 TRIA TRIA +14.71%
Coin of the day
Velas Velas
Inställningar
Språk
SVENSKA
Valuta
USD
Tema
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Rankning i aktier #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Aktiekurs
$0.0416118
Marknadsvärde
$12.78M
Förändring (1 dag)
1.72%
Förändring (1 år)
-22.01%
Land
AU
Handel Noxopharm Limited (NOX)

Kategori

Healthcare
Intäkter för Noxopharm Limited (NOX)
Intäkter i Dec 2025 TTM: $1.11M
Enligt Noxopharm Limited senaste finansiella rapporter är företagets nuvarande intäkter (TTM) $1.11M. År 2024 hade företaget intäkter på $1.60M en minskning jämfört med intäkterna år 2023, som var $4.00M. Intäkter är det totala belopp som ett företag genererar från försäljning av varor eller tjänster. Till skillnad från vinst dras inga kostnader av.
Intäkts­historik för Noxopharm Limited från 2016 till 2026
Intäkter vid slutet av varje år
År Intäkter Ändra
2026 (TTM) $1.11M -40.21%
2025 $1.86M 15.87%
2024 $1.60M -59.98%
2023 $4.00M 6.95%
2022 $3.74M -10.96%
2021 $4.21M -26.42%
2020 $5.71M 116.95%
2019 $2.63M 288.04%
2018 $678.81K 597.95%
2017 $97.26K 0.00%
2016 0.00 0.00%
Intäkter för liknande företag eller konkurrenter
Företag Intäkter Intäktsdifferens Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 4,362,149.84%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 1,084,093.51%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 1,291,639.69%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 817,860.65%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 1,413,432.75%
AU